"MoMed Biotech"

A biotech company that drives innovative drug development by combining advanced artificial intelligence technology with research on the mechanisms of drug targets.

MoMed Biotech was established in April 2022 in Linping District, Hangzhou City. The company's founders are Professor Bai Chen from The Chinese University of Hong Kong, Shenzhen, and Professor Arieh Warshel, a Nobel laureate in Chemistry in 2013. MoMed Biotech's establishment has received strong support from the Linping District government and industrial capital, and it has completed tens of millions of yuan in angel round financing.

MoMed Biotech focuses on the earliest "drug discovery phase" of drug development. Driven by the research on the mechanisms of drug targets and combined with cutting-edge artificial intelligence technology, the company is engaged in the research and development of innovative small molecule drugs, biological macromolecules, and macromolecule-small molecule conjugate drugs. MoMed Biotech is committed to providing a more reliable new drug molecular design method, obtaining lead compounds with higher drug-likeness, improving the efficiency of new drug development, reducing research and development risks, shortening the R&D cycle, and saving industry costs.


MoMed Biotech has creatively proposed the incorporation of dynamic information related to the functional realization of target proteins into the design and development of AI models, and has developed a research and development platform for innovative drug design based on this concept.

This is the first time in the industry, and this research and development method has also been patented. The most crucial dynamic information is based on the computational biology theoretical system established by Professor  Arieh Warshel. Professor Warshel will also provide personal guidance to ensure the smooth progress of mechanism research and the rational effectiveness of data conclusions. Currently, MoMed is the only company in the world that can achieve this.

Based on MoMed Biotech's research and development platform, multiple R&D pipelines are currently in progress. The types of targets we have chosen are diverse and highly representative, including enzymes, ion channels, G-protein-coupled receptors, etc., which are involved in major diseases that threaten contemporary human health such as cancer, cardiovascular diseases, and diabetes. The most advanced pipeline has completed drug design and has entered the phase of molecular synthesis and preclinical biochemical experimental validation.

The biopharmaceutical industry has become a focus of competition in the new round of global development and holds significant strategic importance for national economic growth and the construction of a "Healthy China". For a long time, China's pharmaceutical industry has been in the stage of "following and imitating" foreign drugs, contributing relatively little to global new drug research and development. However, the development of computational biology and artificial intelligence technologies is triggering a "technological revolution" in the biopharmaceutical field. At a critical stage for China's pharmaceutical industry to shift from "following and imitating" to "original innovation," MoMed Biotech is determined to be the "vanguard" of China's innovative medicine, helping the nation to achieve a leapfrog advancement in this field.

Founding Team

Professor Bai Chen

The Founder & CEO

Founder of Momed Biotech (Hangzhou) Co., Ltd., Expert in Computational BiochemistryFormer Associate Researcher at the University of Southern California, Assistant Professor at The Chinese University of Hong Kong, Shenzhen.

Dr. Bai obtained his Bachelor’s and Master’s degrees from Shanghai Jiao Tong University and his PhD degree from Brandeis University (USA) in 2017. After his doctorate, he joined the research group of Professor Arieh Warshel, 2013 Nobel Laureate in Chemistry, as an Associate Researcher, focusing on multi-dimensional modeling and mechanistic studies of large-scale biomolecular machines.

Returning to China in 2020, he joined the School of Medicine at The Chinese University of Hong Kong, Shenzhen, where his research focuses on innovative small and large molecule drug discovery driven by mechanistic studies of drug targets, integrated with cutting-edge artificial intelligence technologies. In 2022, he founded Momed Biotech (Hangzhou) Co., Ltd.

His major academic achievements have been published as first or corresponding author in top international journals, including NATURE CHEMISTRY, ANGEW CHEM INT EDIT, JACS, PNAS, and ACS CENTRAL SCIENCE.



Outstanding Science & Tech Innovation Talent, China High-Tech (MOST）

2024 Scientific Chinese Rising Star in Technology

Zhejiang Province Overseas High-Level Talents

Guangdong Zhujiang Young Top Talent

Shenzhen Pengcheng Scholar

Shenzhen Univ. guest professor

Professor
Arieh WARSHEL

Chief Scientist

Co-Founder of Momed Biotech (Hangzhou) Co., Ltd., 2013 Nobel Laureate in Chemistry, Member of the National Academy of Sciences (USA), Member of the American Academy of Arts and Sciences, and Distinguished Professor at the University of Southern California.

Arieh Warshel was born in 1940 in Kibbutz Sde-Nahum, Israel. From 1958 to 1962, he served in the Israeli Army as a Reserved Rank Captain. He then attended the Technion – Israel Institute of Technology, earning a Bachelor of Science in Chemistry with Highest Honors in 1966.

He pursued graduate studies at the Weizmann Institute of Science, under the supervision of Shneior Lifson, completing a Master of Science in Chemical Physics (1967) and a Doctor of Philosophy in Chemical Physics (1969). After postdoctoral research at Harvard University, he returned to the Weizmann Institute from 1972 to 1976, holding positions as Senior Researcher and Associate Professor.

Professor Warshel and his team developed key computational programs for molecular simulation that are widely applied across diverse fields. They pioneered pivotal methods for simulating biomolecular functions, including introducing molecular dynamics in biological systems, developing quantum mechanics–molecular mechanics approaches, advancing enzyme reaction simulations, initiating microscopic modeling of electron and proton transfer processes in solutions and proteins, pioneering microscopic electrostatic interaction modeling in macromolecules, and introducing simulations of protein folding. His team has recently clarified the molecular origins of the vectorial actions of molecular machines.

2013 Nobel Laureate in Chemistry

Member of the National Academy of Sciences (USA)

Member of the American Academy of Arts and Sciences

Honorary Chairman of the National Academy of Artificial Intelligence (NAAI)

Honorary Fellow of the Royal Society of Chemistry (UK)

Founders Award of the Biophysical Society

Ye Dequan

Chief Pharmacologist

Co-Founder of Momed Biotech (Hangzhou) Co., Ltd., Top 2% Global Scientist (Stanford University), Associate Dean of the School of Medicine, The Chinese University of Hong Kong, Shenzhen, Director of Futian Biomedical Innovation and R&D Center.


Professor Ye obtained his medical bachelor’s degree from Shanghai Second Medical College (now Shanghai Jiao Tong University School of Medicine) and a PhD from Washington University in St. Louis, USA. During his studies and work in the US, he served as Assistant Professor, Associate Professor, and Tenured Professor at the Scripps Research Institute and the University of Illinois College of Medicine. He returned to China in 2010 as a member of the 5th batch of national distinguished experts, successively serving as Dean of the School of Pharmacy at Shanghai Jiao Tong University and Associate Dean of the Institute of Chinese Medical Sciences at the University of Macau. Since February 2019, he has established the School of Life and Health Sciences at The Chinese University of Hong Kong, Shenzhen, serving as its Founding Dean and leading the preparation of the School of Medicine, which was established in 2021. He currently serves as Associate Dean, overseeing all research and innovation affairs.


His research focuses on anti-infection and anti-inflammatory immunity, receptor pharmacology, and studies of innate immunity and inflammation. He has published 240 academic papers in leading international journals such as Blood, Cell, Circ Res, J Clin Invest, Nat Commun, Nat Immunol, and PNAS, with over 20,000 citations and an H-index of 83. In recent years, he has been listed as a Clarivate Highly Cited Researcher, a Top 2% Global Scientist (Stanford University), a China Highly Cited Researcher (Elsevier), and a ScholarGPS Top 0.05% Global Scientist.


With a decade of collaborative R&D experience with pharmaceutical companies including Johnson & Johnson, Novartis, and GSK, and serving as a Senior Advisor to Novartis, he co-founded SiniWest Holdings (developing Class 1 new drugs to Phase III clinical trials) and Torrey Pines Biolabs (antibody R&D). In 2020, he led the establishment of the Futian Biomedical Innovation and R&D Center at The Chinese University of Hong Kong, Shenzhen, in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, serving as its Director to oversee operations and focus on biomedical innovation and technology transfer.


Leader of the Expert Group for the "Biomacromolecules and Microbiome" Key Special Project of the National Key R&D Program

Member of the Academic Committee of Beijing Key Laboratory of Molecular Medicine for Metabolism and Cardiovascular Diseases

Standing Committee Member of the 13th Committee of the Inflammation and Immunopharmacology Professional Committee of the Chinese Pharmacological Society

Founding Dean of the School of Life and Health Sciences, The Chinese University of Hong Kong, Shenzhen

Member of the Technology Transfer Committee, The Chinese Univer